1.045
2.34%
-0.025
Enzo Biochem, Inc. stock is currently priced at $1.045, with a 24-hour trading volume of 23,442.
It has seen a -2.34% decreased in the last 24 hours and a -16.40% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.07 pivot point. If it approaches the $1.04 support level, significant changes may occur.
Previous Close:
$1.07
Open:
$1.07
24h Volume:
23,442
Market Cap:
$53.53M
Revenue:
$20.59M
Net Income/Loss:
$24.31M
P/E Ratio:
-1.1117
EPS:
-0.94
Net Cash Flow:
$-44.02M
1W Performance:
-4.13%
1M Performance:
-16.40%
6M Performance:
-23.16%
1Y Performance:
-57.69%
Enzo Biochem, Inc. Stock (ENZ) Company Profile
Name
Enzo Biochem, Inc.
Sector
Industry
Phone
212-583-0100
Address
527 Madison Avenue, New York, NY
Enzo Biochem, Inc. Stock (ENZ) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-18-11 | Reiterated | Rodman & Renshaw | Mkt Outperform |
Sep-23-09 | Initiated | Rodman & Renshaw | Mkt Outperform |
Sep-13-07 | Initiated | Lazard Capital | Buy |
Enzo Biochem, Inc. Stock (ENZ) Latest News
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Benzinga
Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update
GlobeNewswire Inc.
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments
GlobeNewswire Inc.
HEICO, EMCOR Group And 3 Stocks To Watch Heading Into Monday
Benzinga
ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE
GlobeNewswire Inc.
Steven J. Pully Appointed to Enzo Biochem’s Board of Directors
GlobeNewswire Inc.
Enzo Biochem, Inc. Stock (ENZ) Financials Data
Enzo Biochem, Inc. (ENZ) Revenue 2024
ENZ reported a revenue (TTM) of $20.59 million for the quarter ending October 31, 2023, a +55.67% rise year-over-year.
Enzo Biochem, Inc. (ENZ) Net Income 2024
ENZ net income (TTM) was $24.31 million for the quarter ending October 31, 2023, a +191.46% increase year-over-year.
Enzo Biochem, Inc. (ENZ) Cash Flow 2024
ENZ recorded a free cash flow (TTM) of -$44.02 million for the quarter ending October 31, 2023, a -97.12% decrease year-over-year.
Enzo Biochem, Inc. (ENZ) Earnings per Share 2024
ENZ earnings per share (TTM) was $0.50 for the quarter ending October 31, 2023, a +190.91% growth year-over-year.
About Enzo Biochem, Inc.
Enzo Biochem, Inc., an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 30 patient service centers in New York and New Jersey; and a free standing STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
Cap:
|
Volume (24h):